Skip to content

4Accepted Aug 27, 7:03 PM ET

REGENXBIO Director Gregory Ciongoli Buys Stock, Receives Awards

RGNXREGENXBIO Inc.

Accepted (ET)

7:03 PM

Aug 27, 2026

Filed

Aug 27, 2026

Documents

1

Size

11.8 KB

Summary

REGENXBIO Director Gregory Ciongoli Buys Stock, Receives Awards

Updated

What Happened

  • Gregory Austin Ciongoli, a director of REGENXBIO, made open-market purchases and received equity awards. He purchased 49,196 shares on 2026-08-26 at a weighted average price of $9.14 ($449,706) and 53,407 shares on 2026-08-27 at a weighted average price of $9.36 ($499,676) — a total of 102,603 shares for about $949,382.
  • On 2026-08-25 he was also granted equity awards: 15,432 shares reported as RSUs (time‑based restricted stock units) and 69,609 shares reported as a derivative award (an option grant), both reported at $0 cost in the filing.

Key Details

  • Transaction dates and prices:
    • 2026-08-26: Open‑market purchase, 49,196 shares, weighted avg $9.14 (range $8.67–$9.35). (Footnote F2)
    • 2026-08-27: Open‑market purchase, 53,407 shares, weighted avg $9.36 (range $9.17–$9.4525). (Footnote F3)
    • 2026-08-25: Award grants — 15,432 RSUs (F1) and 69,609 derivative award (option) (F4), both reported at $0.
  • Shares owned after the transactions are not included in the provided excerpt of the Form 4.
  • Notable footnotes:
    • F1: The 15,432 RSUs vest 1/3 on each of Aug 25, 2027, 2028 and 2029, subject to continued service.
    • F4: The option-like award vests 1/3 on Aug 25, 2027, then monthly in equal installments over the next 24 months, subject to service.
    • F2/F3: Purchase prices are weighted averages from multiple trades; the filer can provide trade-by-trade detail on request.
  • Filing timeliness: The report covers transactions on Aug 25–27 and was filed Aug 27, 2026 — within the typical two‑business‑day Form 4 deadline (i.e., timely).

Context

  • The open‑market purchases are direct buys (purchase code P), which some investors consider a stronger signal than awards because they involve the insider deploying personal cash.
  • The grants (code A) are time‑based awards (RSUs and a vesting option) that vest over future service periods and are not immediately marketable shares.
  • All information above is factual from the Form 4; it does not imply motivation for the transactions.

AI-written summary · check the filing